Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Debt Ratios
Coverage Ratios
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency profile exhibits a generally stable capital structure characterized by consistent leverage ratios, though a significant and sustained decline in the ability to cover interest expenses is evident over the observed period.
- Debt-to-Equity and Debt-to-Capital Ratios
- The debt-to-equity ratio remained relatively stable between 0.64 and 0.68 from March 2022 through September 2023. A notable increase occurred toward the end of 2024, peaking at 0.76 in December 2024 before stabilizing around 0.69 to 0.73 in 2025 and 2026. Similarly, the debt-to-capital ratio maintained a tight range around 0.39 to 0.41, with a corresponding peak of 0.43 in December 2024, suggesting a marginal increase in the proportion of debt relative to total capital.
- Debt-to-Assets Ratio
- The proportion of assets financed by debt remained highly consistent, hovering between 0.22 and 0.25 for the majority of the period. A temporary increase to 0.27 was recorded in December 2024, aligned with the peaks seen in other debt ratios, followed by a return to a range of 0.24 to 0.26 through September 2026.
- Financial Leverage
- Financial leverage demonstrated a non-linear pattern, oscillating between a low of 2.66 in September 2024 and a high of 2.92 in March 2023. The ratio shows no long-term upward or downward trend, indicating that the overall multiplier effect of the company's asset base relative to equity has remained constant.
- Interest Coverage Ratio
- A pronounced downward trend is observed in the interest coverage ratio, which declined from 11.01 in March 2022 to 5.33 by September 2026. The degradation was gradual throughout 2022 and 2023, accelerating through 2024 and 2025. This consistent decline indicates a reduction in the margin of safety for meeting interest obligations, suggesting either an increase in debt servicing costs or a contraction in operating earnings.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Equity
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | —) | —) | 724) | 150) | 180) | 360) | 250) | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | ||||||
| Current portion of long-term debt | 375) | 375) | 350) | 1,099) | 749) | 1,648) | 1,643) | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | ||||||
| Long-term debt, less current portion | 30,382) | 30,669) | 30,768) | 30,797) | 31,173) | 28,178) | 28,110) | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | ||||||
| Total debt | 30,757) | 31,044) | 31,842) | 32,046) | 32,102) | 30,186) | 30,003) | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | ||||||
| Shareholders’ equity | 44,681) | 44,883) | 43,902) | 43,882) | 43,953) | 43,722) | 42,503) | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | 0.69 | 0.69 | 0.73 | 0.73 | 0.73 | 0.69 | 0.71 | 0.76 | 0.62 | 0.66 | 0.65 | 0.64 | 0.65 | 0.66 | 0.68 | 0.66 | 0.66 | 0.66 | 0.65 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.61 | 0.64 | 0.65 | 0.25 | 0.25 | 0.27 | 0.27 | 0.30 | 0.38 | 0.38 | 0.38 | 0.38 | 0.41 | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 | ||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Medtronic PLC | 0.57 | 0.60 | 0.60 | 0.59 | 0.54 | 0.58 | 0.58 | 0.50 | 0.49 | 0.49 | 0.49 | 0.47 | 0.55 | 0.51 | 0.44 | 0.46 | 0.48 | 0.49 | 0.50 | ||||||
| UnitedHealth Group Inc. | 0.76 | 0.74 | 0.80 | 0.83 | 0.84 | 0.84 | 0.86 | 0.83 | 0.83 | 0.84 | 0.85 | 0.70 | 0.75 | 0.80 | 0.87 | 0.74 | 0.65 | 0.71 | 0.65 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 30,757 ÷ 44,681 = 0.69
2 Click competitor name to see calculations.
The solvency profile demonstrates a general increase in leverage over the analyzed period, characterized by a steady expansion of both total debt and shareholders' equity, with a notable period of volatility observed in late 2024.
- Total Debt Trends
- Total debt exhibited a gradual increase from 23,255 million USD in March 2022 to 25,120 million USD by December 2023. A significant acceleration in borrowing occurred throughout 2024, with total debt peaking at 31,232 million USD in December 2024. Following this peak, debt levels remained elevated, fluctuating between 30,003 million USD and 32,102 million USD throughout 2025, before trending slightly downward to 30,757 million USD by September 2026.
- Shareholders' Equity Growth
- Equity showed a consistent long-term upward trajectory, rising from 35,975 million USD in March 2022 to 44,681 million USD by September 2026. A temporary contraction was observed in December 2024, where equity decreased to 41,315 million USD, marking a deviation from the general growth trend before resuming an upward climb in 2025.
- Debt to Equity Ratio Analysis
- The debt to equity ratio remained relatively stable, fluctuating between 0.64 and 0.68 from March 2022 through March 2024. A peak ratio of 0.76 was reached in December 2024, directly correlating with the simultaneous increase in total debt and the dip in shareholders' equity. In the subsequent periods from 2025 through September 2026, the ratio established a new baseline, oscillating between 0.69 and 0.73, indicating a sustained increase in financial leverage compared to the 2022-2023 period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Capital
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | —) | —) | 724) | 150) | 180) | 360) | 250) | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | ||||||
| Current portion of long-term debt | 375) | 375) | 350) | 1,099) | 749) | 1,648) | 1,643) | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | ||||||
| Long-term debt, less current portion | 30,382) | 30,669) | 30,768) | 30,797) | 31,173) | 28,178) | 28,110) | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | ||||||
| Total debt | 30,757) | 31,044) | 31,842) | 32,046) | 32,102) | 30,186) | 30,003) | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | ||||||
| Shareholders’ equity | 44,681) | 44,883) | 43,902) | 43,882) | 43,953) | 43,722) | 42,503) | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | ||||||
| Total capital | 75,438) | 75,927) | 75,744) | 75,928) | 76,055) | 73,908) | 72,506) | 72,547) | 70,923) | 69,877) | 67,059) | 64,426) | 63,267) | 63,329) | 62,822) | 60,421) | 59,763) | 59,400) | 59,230) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | 0.41 | 0.41 | 0.42 | 0.42 | 0.42 | 0.41 | 0.41 | 0.43 | 0.38 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.40 | 0.40 | 0.40 | 0.39 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.38 | 0.39 | 0.40 | 0.20 | 0.20 | 0.21 | 0.21 | 0.23 | 0.27 | 0.27 | 0.27 | 0.28 | 0.29 | 0.31 | 0.31 | 0.31 | 0.32 | 0.31 | 0.33 | ||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Medtronic PLC | 0.36 | 0.37 | 0.37 | 0.37 | 0.35 | 0.37 | 0.37 | 0.33 | 0.33 | 0.33 | 0.33 | 0.32 | 0.35 | 0.34 | 0.31 | 0.31 | 0.32 | 0.33 | 0.34 | ||||||
| UnitedHealth Group Inc. | 0.43 | 0.43 | 0.44 | 0.45 | 0.46 | 0.46 | 0.46 | 0.45 | 0.45 | 0.46 | 0.46 | 0.41 | 0.43 | 0.44 | 0.46 | 0.43 | 0.39 | 0.41 | 0.39 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= 30,757 ÷ 75,438 = 0.41
2 Click competitor name to see calculations.
The solvency profile reflects a period of steady expansion in both total debt and total capital from March 2022 through September 2026. While absolute liabilities increased significantly over the timeframe, the capital structure remained balanced, maintaining a relatively stable leverage ratio.
- Total Debt Trends
- A consistent upward trajectory in total debt is observed, rising from 23,255 million US dollars in March 2022 to a peak of 32,102 million US dollars in September 2025. A notable acceleration in borrowing occurred between September 30, 2024, and December 31, 2024, during which total debt increased by approximately 4,084 million US dollars. Following this peak, debt levels entered a period of slight contraction, ending at 30,757 million US dollars by September 30, 2026.
- Total Capital Growth
- Total capital exhibited a sustained increase, growing from 59,230 million US dollars to 75,438 million US dollars over the analyzed period. This growth in the capital base occurred almost concurrently with the increase in debt, suggesting a strategic expansion of the balance sheet to support operational or investment requirements.
- Debt to Capital Ratio Analysis
- The debt to capital ratio remained remarkably stable, fluctuating within a narrow range between 0.38 and 0.43. The ratio reached its maximum value of 0.43 in December 2024, coinciding with the sharpest increase in total debt. However, the ratio quickly reverted to a range of 0.41 to 0.42 for the remainder of the period. The alignment between the growth of total debt and total capital indicates that the organization maintained a consistent target for its long-term solvency and capital structure.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Debt to Assets
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Short-term borrowings | —) | —) | 724) | 150) | 180) | 360) | 250) | 365) | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | ||||||
| Current portion of long-term debt | 375) | 375) | 350) | 1,099) | 749) | 1,648) | 1,643) | 1,649) | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | ||||||
| Long-term debt, less current portion | 30,382) | 30,669) | 30,768) | 30,797) | 31,173) | 28,178) | 28,110) | 29,218) | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | ||||||
| Total debt | 30,757) | 31,044) | 31,842) | 32,046) | 32,102) | 30,186) | 30,003) | 31,232) | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | ||||||
| Total assets | 127,801) | 126,438) | 125,827) | 121,494) | 122,749) | 121,938) | 119,717) | 116,889) | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | 0.24 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 | 0.27 | 0.23 | 0.25 | 0.24 | 0.23 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.29 | 0.30 | 0.31 | 0.15 | 0.15 | 0.16 | 0.16 | 0.17 | 0.20 | 0.20 | 0.20 | 0.20 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | ||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Medtronic PLC | 0.31 | 0.32 | 0.31 | 0.31 | 0.30 | 0.31 | 0.31 | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | 0.27 | 0.28 | 0.28 | ||||||
| UnitedHealth Group Inc. | 0.24 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.23 | 0.22 | 0.23 | 0.25 | 0.23 | 0.20 | 0.22 | 0.21 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= 30,757 ÷ 127,801 = 0.24
2 Click competitor name to see calculations.
The solvency profile of the organization remains stable over the analyzed period, characterized by a consistent balance between debt accumulation and asset growth. While both total debt and total assets increased, the leverage ratio remained within a narrow range, indicating a disciplined approach to capital structure management.
- Total Debt Trends
- Total debt exhibited a general upward trajectory, rising from 23,255 million USD in March 2022 to 30,757 million USD by September 2026. A notable increase occurred between September 2024 and December 2024, where debt rose from 27,148 million USD to 31,232 million USD. Following a peak of 32,102 million USD in September 2025, a gradual decline is observed through the end of the period.
- Asset Growth Analysis
- Total assets demonstrated steady and consistent growth, expanding from 100,486 million USD in March 2022 to 127,801 million USD in September 2026. This growth indicates a continuous expansion of the balance sheet, which served to offset the increase in total liabilities and maintain solvency levels.
- Debt to Assets Ratio Dynamics
- The debt to assets ratio remained remarkably stable for the first several quarters, holding at 0.23 from March 2022 through June 2023. A period of increased leverage began in 2024, reaching a peak ratio of 0.27 in December 2024. Subsequently, the ratio moderated and stabilized between 0.24 and 0.26 throughout 2025 and 2026, suggesting that the organization successfully aligned its debt levels with its asset base expansion.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Financial Leverage
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | 127,801) | 126,438) | 125,827) | 121,494) | 122,749) | 121,938) | 119,717) | 116,889) | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | ||||||
| Shareholders’ equity | 44,681) | 44,883) | 43,902) | 43,882) | 43,953) | 43,722) | 42,503) | 41,315) | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | 2.86 | 2.82 | 2.87 | 2.77 | 2.79 | 2.79 | 2.82 | 2.83 | 2.66 | 2.68 | 2.76 | 2.77 | 2.88 | 2.86 | 2.92 | 2.83 | 2.86 | 2.82 | 2.79 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 2.12 | 2.14 | 2.12 | 1.66 | 1.65 | 1.66 | 1.67 | 1.71 | 1.87 | 1.86 | 1.87 | 1.90 | 1.92 | 1.97 | 1.99 | 2.03 | 2.04 | 2.03 | 2.09 | ||||||
| Intuitive Surgical Inc. | 1.21 | 1.15 | 1.15 | 1.15 | 1.14 | 1.13 | 1.12 | 1.14 | 1.14 | 1.13 | 1.13 | 1.16 | 1.17 | 1.17 | 1.16 | 1.17 | 1.15 | 1.14 | 1.13 | ||||||
| Medtronic PLC | 1.87 | 1.88 | 1.90 | 1.91 | 1.82 | 1.86 | 1.87 | 1.79 | 1.75 | 1.75 | 1.77 | 1.77 | 1.83 | 1.80 | 1.71 | 1.73 | 1.75 | 1.76 | 1.78 | ||||||
| UnitedHealth Group Inc. | 3.19 | 3.15 | 3.19 | 3.29 | 3.29 | 3.26 | 3.26 | 3.22 | 3.17 | 3.20 | 3.28 | 3.08 | 3.34 | 3.40 | 3.49 | 3.16 | 3.26 | 3.16 | 3.04 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 127,801 ÷ 44,681 = 2.86
2 Click competitor name to see calculations.
The organization demonstrated a consistent upward trajectory in total assets and shareholders' equity from March 2022 through September 2026, while maintaining a relatively stable financial leverage ratio. This suggests a disciplined approach to growth, where the expansion of the asset base was supported by a corresponding increase in the capital base.
- Total Asset Expansion
- Total assets grew from 100,486 million US dollars in March 2022 to 127,801 million US dollars by September 2026. The growth was characterized by a steady increase, with a more pronounced acceleration observed between March 2024 and September 2024, where assets rose from 111,894 million to 116,533 million US dollars.
- Shareholders' Equity Development
- Equity increased from 35,975 million US dollars in March 2022 to 44,681 million US dollars by September 2026. While the general trend was positive, a notable contraction occurred in December 2024, where equity dropped to 41,315 million US dollars from a previous high of 43,775 million US dollars in September 2024, before recovering in subsequent quarters.
- Financial Leverage Stability
- The financial leverage ratio fluctuated within a narrow corridor between 2.66 and 2.92. A peak in leverage was recorded in March 2023 at 2.92, followed by a downward trend that reached a minimum of 2.66 in September 2024. The ratio subsequently stabilized, ending the period at 2.86 in September 2026, indicating that the organization has maintained a consistent capital structure relative to its total assets.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Interest Coverage
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Shareholders’ net income | 1,365) | 1,463) | 1,764) | 547) | 1,189) | 1,743) | 2,183) | 418) | 1,016) | 2,300) | 2,246) | 856) | 1,289) | 1,853) | 1,989) | 949) | 1,618) | 1,653) | 1,805) | ||||||
| Add: Net income attributable to noncontrolling interest | (22) | (9) | (4) | (1) | (2) | 1) | 1) | (5) | (8) | 1) | 3) | (25) | 11) | 3) | 15) | 12) | (5) | (3) | (10) | ||||||
| Add: Income tax expense | 451) | 483) | 544) | (331) | 219) | 548) | 613) | 193) | 365) | 685) | 690) | 170) | 354) | 585) | 615) | 193) | 533) | 493) | 531) | ||||||
| Add: Interest expense | 358) | 364) | 357) | 366) | 351) | 341) | 344) | 340) | 300) | 280) | 265) | 259) | 259) | 261) | 251) | 229) | 213) | 208) | 201) | ||||||
| Earnings before interest and tax (EBIT) | 2,152) | 2,301) | 2,661) | 581) | 1,757) | 2,633) | 3,141) | 946) | 1,673) | 3,266) | 3,204) | 1,260) | 1,913) | 2,702) | 2,870) | 1,383) | 2,359) | 2,351) | 2,527) | ||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Interest coverage1 | 5.33 | 5.08 | 5.39 | 5.79 | 6.16 | 6.33 | 7.14 | 7.67 | 8.52 | 9.07 | 8.70 | 8.49 | 8.87 | 9.76 | 9.95 | 10.13 | 10.75 | 10.71 | 11.01 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 7.59 | 10.81 | 16.18 | 18.17 | 16.99 | 15.90 | 14.40 | 13.55 | 12.65 | 11.74 | 11.46 | 11.46 | 10.79 | 11.34 | 13.06 | 15.89 | 18.41 | 20.07 | 18.10 | ||||||
| Medtronic PLC | 8.81 | 9.03 | 8.67 | 8.72 | 7.89 | 7.72 | 7.65 | 7.73 | 8.87 | 8.97 | 9.90 | 9.43 | 10.15 | 11.02 | 10.88 | 10.98 | 10.95 | 10.18 | 5.65 | ||||||
| UnitedHealth Group Inc. | 6.12 | 5.48 | 4.68 | 4.67 | 6.51 | 7.48 | 7.94 | 6.14 | 6.39 | 6.79 | 7.53 | 9.97 | 10.21 | 10.99 | 12.25 | 13.59 | 14.66 | 14.45 | 14.26 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Interest coverage
= (EBITQ3 2026
+ EBITQ2 2026
+ EBITQ1 2026
+ EBITQ4 2025)
÷ (Interest expenseQ3 2026
+ Interest expenseQ2 2026
+ Interest expenseQ1 2026
+ Interest expenseQ4 2025)
= (2,152 + 2,301 + 2,661 + 581)
÷ (358 + 364 + 357 + 366)
= 5.33
2 Click competitor name to see calculations.
An analysis of the interest coverage ratio reveals a sustained long-term decline from March 2022 through September 2026. The ratio decreased from a peak of 11.01 to 5.33, indicating a reduction in the margin of safety available to meet interest obligations from operating profits.
- Earnings Before Interest and Tax (EBIT) Trends
- EBIT exhibits significant quarterly volatility with a pronounced seasonal pattern. A recurring decline is observed every December, with the lowest point occurring in December 2025 at 581 million. Despite periodic peaks, such as the 3,266 million recorded in June 2024, the earnings profile demonstrates instability that contributes to fluctuations in solvency metrics.
- Interest Expense Trajectory
- A consistent upward trend in interest expenses is evident throughout the analyzed period. Expenses rose steadily from 201 million in March 2022 to 358 million by September 2026. This monotonic increase suggests an expansion of the debt load or an increase in the cost of servicing existing debt.
- Interest Coverage Ratio Dynamics
- The interest coverage ratio has undergone a steady contraction, driven by the combination of rising interest costs and inconsistent EBIT. The ratio remained relatively stable above 10.00 during 2022 but began a more accelerated decline after March 2023. The most significant erosion occurred between March 2024 and June 2026, during which the ratio fell from 8.70 to a period low of 5.08. While a marginal recovery to 5.33 was noted in the final quarter, the overall capacity to cover interest expenses has diminished substantially over the five-year window.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?